Life Sciences Firm Cure Ventures Announces $350M Fund
Gunderson Dettmer represented client Cure Ventures in the formation of its $350 million inaugural fund. Cure Ventures invests in early-stage life sciences and biotechnology companies with a primary focus on groundbreaking curative technologies.
In the announcement of the fund formation, Cure Ventures’ co-founder and managing partner Richard Lim said, “Biopharma venture capital is an enterprise in risk management that demands rigor, diligence and patience. At Cure, we aren’t just signing a check. We are committed to working closely with founders to collaborate and operationalize capital, making us a true sweat equity partner."
The Gunderson Dettmer deal team was led by Malcolm Nicholls and included Nick Dawson and Hannah Carlson.
Companies
Cure Ventures
Featured Insights
Featured Insights
Client News
Client News
Client News